Zoetis (ZTS)
(Real Time Quote from BATS)
$192.69 USD
+0.05 (0.03%)
Updated Sep 23, 2024 11:18 AM ET
2-Buy of 5 2
C Value D Growth F Momentum F VGM
Company Summary
Parsippany, NJ-based Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. The entity started trading on the NYSE on Feb 1, 2013, under the name Zoetis. The company is a leader in the animal health space, which focuses on livestock and companion animals in eight major product categories: vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, pain and sedation, medicated feed additives and animal health diagnostics. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (...
Company Summary
Parsippany, NJ-based Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. The entity started trading on the NYSE on Feb 1, 2013, under the name Zoetis. The company is a leader in the animal health space, which focuses on livestock and companion animals in eight major product categories: vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, pain and sedation, medicated feed additives and animal health diagnostics. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
The outstanding growth rate in the companion animal medicines, vaccines and diagnostics sector is being driven by economic development, related increases in disposable income and a rise in pet ownership and spending on pet care.
Zoetis has been working on strengthening its product portfolio through acquisitions and deals. In 2023, the company acquired two privately held research and development stage animal health biopharmaceutical companies, PetMedix Ltd. and adivo GmbH. PetMedix develops antibody-based therapeutics for companion animals, which is expected to strengthen Zoetis’ companion animal products portfolio.
Zoetis has consolidated its four-region structure into a two-region structure, namely the United States and International. Total revenues grew 6% year over year to $8.54 billion in 2023. The United States contributed 53% of total revenues in 2023 while international revenues contributed the rest.
In 2023, Zoetis’ two top-selling products and product lines were Simparica/Simparica Trio and Apoquel/Apoquel Chewable, contributing approximately 13% and 10%, respectively, of its revenues.
General Information
Zoetis Inc
10 Sylvan Way
Parsippany, NJ 07054
Phone: 973-822-7000
Fax: 302-655-5049
Email: steve.frank@zoetis.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Earnings Date | 11/4/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.46 |
Current Year EPS Consensus Estimate | 5.83 |
Estimated Long-Term EPS Growth Rate | 11.20 |
Earnings Date | 11/4/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 192.64 |
52 Week High | 201.92 |
52 Week Low | 144.80 |
Beta | 0.88 |
20 Day Moving Average | 1,801,635.75 |
Target Price Consensus | 220.15 |
4 Week | 6.49 |
12 Week | 11.12 |
YTD | -2.40 |
4 Week | 5.22 |
12 Week | 6.40 |
YTD | -18.36 |
Shares Outstanding (millions) | 453.05 |
Market Capitalization (millions) | 87,275.73 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.90% |
Annual Dividend | $1.73 |
Payout Ratio | 0.31 |
Change in Payout Ratio | 0.06 |
Last Dividend Payout / Amount | 7/18/2024 / $0.43 |
Fundamental Ratios
P/E (F1) | 33.06 |
Trailing 12 Months | 34.77 |
PEG Ratio | 2.96 |
vs. Previous Year | 10.64% |
vs. Previous Quarter | 13.04% |
vs. Previous Year | 8.30% |
vs. Previous Quarter | 7.81% |
Price/Book | 17.72 |
Price/Cash Flow | 30.00 |
Price / Sales | 9.79 |
6/30/24 | 50.67 |
3/31/24 | 50.34 |
12/31/23 | 51.25 |
6/30/24 | 17.88 |
3/31/24 | 17.59 |
12/31/23 | 17.58 |
6/30/24 | 3.45 |
3/31/24 | 3.33 |
12/31/23 | 3.36 |
6/30/24 | 2.09 |
3/31/24 | 1.94 |
12/31/23 | 2.00 |
6/30/24 | 28.52 |
3/31/24 | 28.44 |
12/31/23 | 28.76 |
6/30/24 | 26.29 |
3/31/24 | 27.38 |
12/31/23 | 27.43 |
6/30/24 | 32.46 |
3/31/24 | 34.19 |
12/31/23 | 34.36 |
6/30/24 | 10.87 |
3/31/24 | 11.07 |
12/31/23 | 10.87 |
6/30/24 | 1.03 |
3/31/24 | 0.98 |
12/31/23 | 0.97 |
6/30/24 | 1.32 |
3/31/24 | 1.30 |
12/31/23 | 1.32 |
6/30/24 | 56.96 |
3/31/24 | 56.50 |
12/31/23 | 56.81 |